ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

13th November 2026

Listing Department,
Metropolitan Stock Exchange of India Limited,
Unit 205A, 2nd Floor, Building A,
Piramal Agastya Corporate Park,
Lal Bahadur Shastri Marg,
Kurla (West), Mumbai- 400070.

Dear Sirs,

Sub: Outcome of Board Meeting

Further to our letter dated 3rd November 2026, we wish to inform you that the Board of Directors of the Company at its Meeting held on Friday, 13th November, 2026 at 11.00 am has interalia considered and approved the following:

1. Un-audited Financial Results for the Quarter and half year ended 30th September, 2026 in terms of Regulation 33 of SEBI (LODR) Regulations, 2015 along with Limited Review Report attached as ***Annexure A.***

2. A declaration for Regulation 32 Non-applicability of Statement of Deviation or Variation for proceeds of Public Issue or Rights Issue or Preferential Issue or Qualified Institutional Placement (QIP) etc.– ***Annexure B***

Board Meeting concluded at 2.05 pm.

Please take the above information on your records.

Thanking you,

Yours faithfully,
For **Anglo-French Drugs & Industries Ltd.**

Sriee Aneetha M
Company Secretary & Compliance Officer

Encl: a.a

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

REGD. OFF: No. 101 1ST FLOOR, ORBIT PLAZA NEW PRABHADEVI ROAD PRABHADEVI MUMBAI 400025

CIN: L24230MH1923PLC463682

WEBSITE: www. afdil.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026

(Rs. In Lacs)

PARTICULARS	Quarter Ended			Six month ended		Period Ended
	3 months ended (30/09/2026) (Un-Audited)	3 months ended (30/06/2026) (Un-Audited)	Corresponding 3 months Ended (30/09/2025) Un-audited	6 months ended (30/09/2026) (Un-Audited)	Corresponding 6 Months ended (30/09/2025) (Un-Audited)	Year Ended (31/03/2026) (Audited)
1. Income						
(a) Revenue from operations	1,979	1,588	2,001	3,567	4,724	9,032
(b) Other Income	413	931	687	1,344	4,335	3,906
Total Income	**2,392**	**2,520**	**2,688**	**4,911**	**9,059**	**12,938**
2. Expenses						
(a) Cost of Material Consumed	242	238	231	480	867	1,771
(b) Purchase of Stock in Trade	1,204	942	1,205	2,146	2,157	4,515
(c) Changes in Inventories of Finished goods, work in progress & Stock in Trade	33	(25)	274	8	602	613
(d) Cost of Goods Sold (a+b+c)	**1,479**	**1,155**	**1,710**	**2,634**	**3,626**	**6,899**
(e) Employee Benefits Expenses	430	379	387	809	788	1,574
(f) Finance costs	63	56	58	119	106	202
(g) Depreciation and Amortisation Expenses	79	62	78	141	157	328
(h) Other Expenses	373	474	290	847	725	1,482
Total Expenses (d+e+f+g+h)	**2,424**	**2,126**	**2,523**	**4,550**	**5,402**	**10,485**
3. Profit(+)/Loss(-) before Exceptional items (1-2)	**(33)**	**394**	**165**	**361**	**3,657**	**2,453**
4. Exceptional items (Exp)	(2)	-	174	(2)	174	174
5. Profit(+)/Loss(-) before Tax (3+4)	**(31)**	**394**	**(9)**	**363**	**3,483**	**2,279**
6. Tax Expenses						
i) Current Tax	-	-	-	-	-	
ii) Deferred tax	-	-	-	-	-	(5)
iii) Buyback Tax	-	-	-	-	-	-
iv) Tax effect on items reclassified	-		-	-	-	-
7. Profit(+)/Loss(-) for the period (5-6)	**(31)**	**394**	**(9)**	**363**	**3,483**	**2,284**
8. Other Comprehensive Income						
(i)Items that will not be reclassified to profit & Loss	(3)	3	-	(0)	3	1
(ii)Income tax on items that will not be reclassified to profit or loss	-	-	-	-	-	-
Total Other Comprehensive Income	**(3)**	**3**	**-**	**(0)**	**3**	**1**
9. Total Comprehensive Income (7+8)	**(34)**	**397**	**(9)**	**363**	**3,486**	**2,285**
10. Paid up equity share capital (Face value of Rs. 10 each)	113	113	113	113	113	113
Reserves excluding revaluation reserve						14,636
11. Earnings/(Loss) Per Share (Face value of Rs. 10 each)						
a) Basic	(3)	35	(1)	32	309	202
b) Diluted	(3)	35	(1)	32	309	202

NOTES:

1) This statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

2) The above Results were taken on record at the meeting of Board of Directors held on 13-11-2026. The results have been reviewed by the Statutory Auditor.

3) The Company has two reportable segments as per Ind AS- Pharmaceuticals division and Investment division

4) The Company submitted an application to the Metropolitan Stock Exchange of India Limited (MSE) on October 1, 2025, in accordance with Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, seeking approval for the proposed Scheme of Demerger between Anglo-French Drugs and Industries Limited (the "Demerged Company") and AFD Enterprises Limited (the "Resulting Company"). The Company has received the No Objection Certificate (NOC) from MSE on March 5, 2026, and had filed the requisite application with the National Company Law Tribunal (NCLT) for its approval of the Scheme on 8th July, 2026.

5) The figures in respect of previous period have been regrouped/recast wherever necessary.

ANGLO-FRENCH DRUGS & INDUSTRIES LTD

MANAGING DIRECTOR
NIRBHAY KANORIA
DIN: 02558300

PLACE: Mumbai
DATE: 13-11-2026

KAMG & ASSOCIATES Kolkata Chartered Accountants

Anglo-French Drugs & Inds. Ltd. Mumbai

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED
REGD. OFF: No. 101 1ST FLOOR, ORBIT PLAZA NEW PRABHADEVI ROAD PRABHADEVI MUMBAI 400025
CIN: L24230MH1923PLC463682

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2026

(Rs. In Lacs)

	Particulars	Note No.	As at September 30th,2026	As at March 31st, 2026
			Unaudited	Audited
	ASSETS			
1	**Non-current assets**			
	Property, plant and equipment	3	2,310	2,339
	Capital work-in-progress			
	Right of Use of Assets	4	387	148
	Intangible Assets	5	2	2
	Financial Assets			
	Investments	6	48	48
	Other Financial Assets	7	140	179
	Deferred tax assets (Net)	8	-	-
	Other Non Current Assets	9	-	-
	Subtotal (A)		**2,886**	**2,715**
2	**Current assets**			
	Inventories	10	516	488
	Financial Assets			
	(i) Trade Receivables	11	2,124	2,239
	(ii) Cash and cash equivalents	12 (a)	132	39
	(iii) Bank balances other than (ii) above	12 (b)	-	24
	(iv) Investments	13	13,494	13,139
	(iv) Other financial assets	14	2,108	1,788
	Current Tax Assets (Net)	15		
	Other current assets	16	99	134
	Subtotal (B)		**18,474**	**17,852**
	TOTAL ASSETS(A+B)		**21,361**	**20,567**
	EQUITY AND LIABILITIES			
1	**Equity**			
	Equity Share capital	17	113	113
	Other Equity	18	14,981	14,636
	Subtotal (C)		**15,094**	**14,749**
	LIABILITIES			
2	**Non Current Liabilities**			
	Financial liabilities			
	Borrowings	19	285	136
	Other financial liabilities	20	87	26
	Deferred tax liabilities (net)	21	28	28
	Other Non Current Liabilities	22	407	160
	Long Term provisions	23	246	246
	Subtotal (D)		**1,053**	**595**
3	**Current liabilities**			
	Financial Liabilities			
	(i) Borrowings	24	2,403	2,023
	(ii) Trade Payables			
	a) Total outstanding dues of Micro and Small Enterprises	25		410
	b) Total outstanding dues other than Micro and Small Enterprises		1,901	1,690
	(iv) Other current financial liabilities	26	773	947
	Short term Provisions	27	27	27
	Current Tax Liabilities/ (Asset)	15	112	126
	Subtotal (E)		**5,214**	**5,224**
	TOTAL EQUITY AND LIABILITIES(C+D+E)		**21,361**	**20,567**

KAMG & ASSOCIATES Kolkata Chartered Accountants

FOR ANGLO FRENCH DRUGS & INDUSTRIES LIMITED

Anglo-French Drugs & Inds. Ltd. Mumbai

MANAGING DIRECTOR

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

REGD. OFF: No. 101 1ST FLOOR, ORBIT PLAZA NEW PRABHADEVI ROAD PRABHADEVI MUMBAI 400025

CIN: L24230MH1923PLC463682

Statement of Profit and Loss for the six months ended 30th September, 2026

(Rs. In Lacs)

	Particulars	Note No.	For the six months ended September 30, 2026	For the period ended March 31st, 2026
	CONTINUING OPERATIONS			
1	**Income**			
	Revenue from operations	28	3,567	9,032
	Other income	29	1,344	3,904
	Total Revenue		**4,911**	**12,936**
2	**Expenses**			
	Cost Of Materials Consumed	30	480	1,771
	Purchases of Stock-in-Trade	31	2,146	4,515
	Changes in inventories of Finished Goods, Work in Progress and Stock in Trade	32	8	612
	Employee benefits expense	33	809	1,658
	Finance costs	34	119	202
	Depreciation and amortization expense	35	141	328
	Other expenses	36	847	1,400
	Total Expenses		**4,550**	**10,486**
3	**Profit/(loss) before exceptional items and tax**		**361**	**2,451**
4	Exceptional items	36(A)	-2	174
5	**Profit before tax**		**363**	**2,277**
6	**Tax expense:**			
	Current tax			
	Deferred tax	37	-	(5)
	Tax effect on items reclassified			
7	**Profit/ (Loss) for the year**		**363**	**2,281**
8	**Other Comprehensive Income**			
	A. (i) Items that will not be reclassified to Profit or Loss			
	- Remeasurement of Post-employment benefit obligations		-	4
	- Change in equity instruments- Fair value through Other Comprehensive Income	-	(0)	1
	Income tax relating to the above			
	B (i) Items that will be reclassified to Profit or Loss			
	Income tax relating to the above			
	Total Other Comprehensive Income / (Loss)		**(0)**	**5**
	Total Comprehensive Income for the year		**363**	**2,286**
	Earnings per share (Face value Rs.10/-) basic and Diluted			
	(Refer Note 38 to the Financial Statements)		**32**	**202**

KAMG & ASSOCIATES Kolkata Chartered Accountants

FOR ANGLO FRENCH DRUGS & INDUSTRIES LIMITED

Anglo-French Drugs & Inds. Ltd. Mumbai

MANAGING DIRECTOR

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED
REGD. OFF: No. 101 1ST FLOOR, ORBIT PLAZA NEW PRABHADEVI ROAD PRABHADEVI MUMBAI 400025
CIN: L24230MH1923PLC463682

STATEMENT OF CASH FLOWS FOR THE SIX MONTHS ENDED 30TH SEPTEMBER, 2026

(Rs. In Lacs)

Particulars	For the six months ended September 30th, 2026	For the year ended Mar 31st, 2026
	Unaudited	Audited
Cash flow from operating activities		
Profit before tax	363	2,277
Adjustments for :		
Depreciation and amortisation	141	328
Interest expense	119	202
Interest income	(58)	(398)
Gain on termination of ROU	-	(28)
Employee benefit expense - Actuarial gain	-	4
(Gain)/loss on Investment	(1,268)	(3,424)
provision / liability written back	-	(7)
loss on sale of asset	1	0
Dividend income	(12)	(17)
Operating profit before working capital changes	(713)	(1,064)
Adjustments for changes in :		
(Increase)/Decrease Trade Receivables	115	971
(Increase)/Decrease Inventories	(28)	662
(Increase)/Decrease in Financial Assets (Current)	(281)	519
(Increase)/Decrease in Other assets (Current)	35	(48)
Increase/(Decrease) in Trade payables	(200)	(748)
Increase/(Decrease) in Financial liabilities (Current)	(113)	(149)
Increase/(Decrease) in Other liabilities (Current)	-	(9)
Increase/(Decrease) in Other liabilities (Non-Current)	-	(276)
Increase/(Decrease) in Financial liabilities (Non-current)		
Increase/(Decrease) in employee benefit	-	30
Cash generated from operations		
Income tax refund received / (paid) (net)	(15)	(53)
Net cash flow from operating activities before exceptional items	(1,200)	(166)
Exceptional items		174
Net cash flow from operating activities [A]	(1,200)	8
Cash flow from investing activities		
Payments for acquisition of assets	-88	-328
Proceeds from disposal of Fixed Assets	7	
Gain on termination of ROU	-	28
Investments(Current and Non-current)	913	(212)
Investment in bank deposits	24	70
Dividend Received	12	17
Interest received	58	398
Net cash flow used in investing activities [B]	926	(28)
Cash flow from financing activities		
Changes in long term borrowings	149	(273)
Changes in short term borrowings	379	529
Interest paid - Net	(119)	(202)
Lease Liability – Principal Payment	(25)	
Dividend paid and tax thereon	(17)	(17)
Net cash flow from financing activities [C]	367	37
Net cash inflow / (outflow) D = [A+B+C]	93	17
Opening cash and cash equivalents [E]	39	22
Closing cash and cash equivalents F= [D+E]	132	39

Note:
(a) The above cash flow statement has been prepared under the "Indirect Method" as set out in Ind AS 7- Statement of Cash Flow".

KAMG & ASSOCIATES Kolkata Chartered Accountants

Anglo-French Drugs & Inds. Ltd. Mumbai

FOR ANGLO FRENCH DRUGS & INDUSTRIES LIMITED

NK

MANAGING DIRECTOR

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED
REGD. OFF: No. 101 1ST FLOOR, ORBIT PLAZA NEW PRABHADEVI ROAD PRABHADEVI MUMBAI 400025
CIN: L24230MH1923PLC463682
WEBSITE: www. afdil.com

A) Segment wise revenue, results for the quarter and six months ended 30th September 2026

(Rs. In Lacs)

Sl. No	Particulars	Quarter ended			Six months period ended		Year ended
		3 Months ended 30-Sep-2026	3 months ended 30-June-2026	Corresponding 3 months ended 30-Sept-2025	Year to Date figures for current period ended 30-sept - 2026	Year to Date figures for Previous period ended 30-sept - 2025	Year to date figures for previous year ended 31-Mar-2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Segment revenue**						
	(a) Pharmaceuticals	1,930	1,561	2,001	3,491	4,724	5,310
	(b) Investments	429	927	637	1,356	4,254	3,722
	Total	**2,359**	2,488	2,638	4,847	8,978	9,032
	Less: Inter-segment revenue		-				-
	Net income from operations	**2,359**	**2,488**	**2,638**	**4,847**	**8,978**	**9,032**
2	**Segment results**						
	(a) Pharmaceuticals	-342	(446)	(566)	(787)	(526)	(4,756)
	(b) Investments	278	809	507	1,086	3,931	3,129
	Total Segment result	**-64**	**363**	**(59)**	**299**	**3,405**	**(1,627)**
	Add: Other income	33	31	50	64	80	3,904
	Total profit/(loss) before tax	**-31**	**394**	**(9)**	**363**	**3,485**	**2,280**

B) Segment wise Assets & Liabilities for the quarter and six months ended 30th September 2026

Sl. No	Particulars	Quarter ended			Six months period ended		Year ended
		3 Months ended 30-Sep-2026	3 months ended 30-June-2026	Corresponding 3 months ended 30-Sept-2025	Year to Date figures for current period ended 30-sept - 2026	Year to Date figures for Previous period ended 30-sept - 2025	Year to date figures for previous year ended 31-Mar-2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Segment Assets**						
	(a) Pharmaceuticals	7,819	6,916	7,981	7,819	7,981	7,380
	(b) Investments	13,542	13,694	13,816	13,542	13,816	13,187
	Total	**21,361**	**20,610**	**21,797**	**21,361**	**21,797**	**20,567**
2	**Segment Liabilities**						
	(a) Pharmaceuticals	6,115	5,315	5,719	6,115	5,719	20,435
	(b) Investments	152	150	129	152	129	132
	Total	**6,267**	**5,465**	**5,848**	**6,267**	**5,848**	**20,567**

KAMG & ASSOCIATES Kolkata Chartered Accountants

Anglo-French Drugs & Inds. Ltd. Mumbai

FOR ANGLO FRENCH DRUGS & INDUSTRIES LIMITED

MANAGING DIRECTOR

KAMG & ASSOCIATES
CHARTERED ACCOUNTANTS

AE - 350, Salt Lake, Sector- I, Kolkata - 700 064
Office > +91-33- 23591111 / 23592222
E-mail > CA@kamg.in • Website > www.kamg.in

Independent Auditors' Review Report on Unaudited Financial Results of Anglo French Drugs and Industries Limited for the quarter and six months ended 30th September, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
Anglo French Drugs and Industries Limited,
Bengaluru

1. We have reviewed the accompanying Statement of unaudited financial results of **Anglo French Drugs and Industries Limited** ("the Company") for the quarter and half year ended 30th September, 2026 ("the Statement"), attached herewith being submitted by the Company as per the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical procedures and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, apart from the matters indicated below under 'Emphasis of Matter', nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

Attention is drawn to the following :

The Company had submitted an application to the Metropolitan Stock Exchange of India Limited (MSE) on October 1, 2025, in accordance with Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, seeking approval for the proposed Scheme of Demerger between Anglo-French Drugs and Industries Limited (the "Demerged Company") and AFD Enterprises Limited (the "Resulting Company"). The Company had received the No Objection Certificate (NOC) from MSE on March 5, 2026, and had filed the requisite application with the National Company Law Tribunal (NCLT) for its approval of the Scheme on 8th July, 2026.

Our conclusion is not modified in respect of the matter.

For **KAMG & ASSOCIATES**
Chartered Accountants
(Firm Registration No. 311027E)



Amitabha Niyogi

Amitabha Niyogi
Partner
(Membership No. 056720)
UDIN: 26056720ECZSW19283

Place: Kolkata
Date: November 13, 2026

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

13th November 2026

To,
Listing Department,
Metropolitan Stock Exchange of India Limited,
Unit 205A, 2nd Floor, Building A,
Piramal Agastya Corporate Park,
Lal Bahadur Shastri Marg,
Kurla (West), Mumbai- 400070.

Dear Sir,

Sub: Undertaking about Non Applicability of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and half year ended 30th September, 2026

Ref: Symbol: AFDIL, Series: BE

Pursuant to the Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we confirm that **'Statement of Deviation or Variation for proceeds of public issue or rights issue or preferential issue or Qualified Institutions Placement (QIP) etc.,'** is not applicable to our Company, for the quarter and half year ended 30th September 2026.

Kindly take the same on your records and oblige.

Thanking You,

Yours Faithfully,
For Anglo-French Drugs & Industries Limited

Sriee Aneetha M
Company Secretary & Compliance Officer

Registered Office: No.101, First Floor, Orbit Plaza, New Prabhadevi Road, Prabhadevi, Mumbai– 400025, Maharashtra, India
Head Office: Plot No.4, Phase-II, Peenya Industrial Area, Peenya, Bangalore-560 058
Tel.: 080 – 2315 4770 E-mail: contact@afdil.comWebsite:www.afdil.com
CIN No: L24230MH1923PLC463682 GST No.: 29AAACA9756E1ZH